MedPath

Chlorpromazine

Generic Name
Chlorpromazine
Drug Type
Small Molecule
Chemical Formula
C17H19ClN2S
CAS Number
50-53-3
Unique Ingredient Identifier
U42B7VYA4P
Background

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.

Indication

For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.

Associated Conditions
Acute Intermittent Porphyria (AIP), Apprehension, Defiant Disorder, Oppositional, Intractable hiccups, Mania, Nausea and vomiting, Restlessness, Schizophrenia, Tetanus, Severe behavioural problems, Short term Hyperactivity

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Phase 1
Recruiting
Conditions
Acute Ischemic Stroke
Interventions
Drug: Placebo group
Procedure: endovascular thrombectomy
First Posted Date
2024-10-29
Last Posted Date
2024-12-20
Lead Sponsor
Capital Medical University
Target Recruit Count
32
Registration Number
NCT06663631
Locations
🇨🇳

Linyi People's Hospital, Linyi, Shandong, China

Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets

Phase 1
Completed
Conditions
Healthy Subject
Interventions
First Posted Date
2023-12-04
Last Posted Date
2023-12-08
Lead Sponsor
Whanin Pharmaceutical Company
Target Recruit Count
70
Registration Number
NCT06154434
Locations
🇰🇷

Whan In Pharm., Seoul, Korea, Republic of

Correlation of Genetic Variations With Clinical Response in Substance Use Disorder

First Posted Date
2023-04-27
Last Posted Date
2023-04-27
Lead Sponsor
Alexandria University
Target Recruit Count
200
Registration Number
NCT05833399
Locations
🇪🇬

Alexandria University, Alexandria, Egypt

Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Phase 1
Withdrawn
Conditions
Colon Cancer Stage III
Interventions
First Posted Date
2022-06-27
Last Posted Date
2022-10-27
Lead Sponsor
Sadat City University
Registration Number
NCT05433402
Locations
🇪🇬

Faculty of Pharmacy, University of Sadat city, Sadat City, Menoufia, Egypt

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Phase 2
Recruiting
Conditions
Neuroleptics
Delirium
Epileptics
Interventions
First Posted Date
2022-06-24
Last Posted Date
2025-05-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05431595
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Chlorpromazine and Standard of Care in Glioblastoma

Phase 1
Active, not recruiting
Conditions
Glioblastoma Multiforme
Interventions
Radiation: Radiation Therapy
First Posted Date
2022-01-13
Last Posted Date
2023-08-29
Lead Sponsor
Mohammed Milhem
Target Recruit Count
10
Registration Number
NCT05190315
Locations
🇺🇸

University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

Repurposing of Chlorpromazine in Covid-19 Treatment

Phase 3
Withdrawn
Conditions
COVID-19
Interventions
Combination Product: Standard of Care (SOC)
First Posted Date
2020-04-29
Last Posted Date
2024-07-10
Lead Sponsor
Centre Hospitalier St Anne
Registration Number
NCT04366739
Locations
🇫🇷

Centre Hospitalier Sainte-Anne, Paris, France

Administration of Chlorpromazine as a Treatment for COVID-19

Phase 2
Conditions
COVID-19
Interventions
First Posted Date
2020-04-21
Last Posted Date
2020-07-08
Lead Sponsor
Cairo University
Target Recruit Count
100
Registration Number
NCT04354805
Locations
🇪🇬

Cairo University, Cairo, Egypt

Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures

Conditions
Children Sedation
Interventions
First Posted Date
2020-04-17
Last Posted Date
2020-04-17
Lead Sponsor
University Hospital, Brest
Target Recruit Count
254
Registration Number
NCT04350528
Locations
🇫🇷

CHRU de Brest, Brest, France

Repurposing Chlorpromazine in the Treatment of Glioblastoma

Phase 2
Conditions
Glioblastoma Multiforme
MGMT-Unmethylated Glioblastoma
Interventions
First Posted Date
2020-01-13
Last Posted Date
2020-01-13
Lead Sponsor
Marco G Paggi, MD, PhD
Target Recruit Count
41
Registration Number
NCT04224441
Locations
🇮🇹

Regina Elena Cancer Institute, Roma, Lazio, Italy

🇮🇹

Carlo Besta Neurological Institute, Milano, Lombardia, Italy

🇮🇹

Istituto Oncologico Veneto, Padova, Veneto, Italy

© Copyright 2025. All Rights Reserved by MedPath